Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple ...
In this installment of Chief Insights in Oncology, John M. Burke, MD, co-editor in chief of Targeted Therapies in Oncology, discusses his column from the September II 2025 issue.
An analysis found that MS patients on a less frequent anti-CD20 therapy dosing schedule do not have more relapses or show ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback